Logo image of JNH.CA

JACK NATHAN MEDICAL CORP (JNH.CA) Stock Fundamental Analysis

TSX-V:JNH - TSX Venture Exchange - CA4663771083 - Common Stock - Currency: CAD

0.005  0 (0%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to JNH. JNH was compared to 16 industry peers in the Health Care Providers & Services industry. JNH has a bad profitability rating. Also its financial health evaluation is rather negative. JNH has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year JNH has reported negative net income.
JNH had a negative operating cash flow in the past year.
In the past 5 years JNH always reported negative net income.
JNH had a negative operating cash flow in each of the past 5 years.
JNH.CA Yearly Net Income VS EBIT VS OCF VS FCFJNH.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 2M -2M -4M -6M -8M -10M

1.2 Ratios

With a Return On Assets value of -155.33%, JNH is not doing good in the industry: 81.25% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -155.33%
ROE N/A
ROIC N/A
ROA(3y)-87.41%
ROA(5y)-87.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JNH.CA Yearly ROA, ROE, ROICJNH.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 600 800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for JNH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JNH.CA Yearly Profit, Operating, Gross MarginsJNH.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

0

2. Health

2.1 Basic Checks

JNH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for JNH has been increased compared to 1 year ago.
JNH has more shares outstanding than it did 5 years ago.
JNH has a worse debt/assets ratio than last year.
JNH.CA Yearly Shares OutstandingJNH.CA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
JNH.CA Yearly Total Debt VS Total AssetsJNH.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

JNH has an Altman-Z score of -9.29. This is a bad value and indicates that JNH is not financially healthy and even has some risk of bankruptcy.
JNH has a Altman-Z score of -9.29. This is in the lower half of the industry: JNH underperforms 75.00% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.29
ROIC/WACCN/A
WACC4.14%
JNH.CA Yearly LT Debt VS Equity VS FCFJNH.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

JNH has a Current Ratio of 0.35. This is a bad value and indicates that JNH is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of JNH (0.35) is worse than 68.75% of its industry peers.
JNH has a Quick Ratio of 0.35. This is a bad value and indicates that JNH is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.35, JNH is not doing good in the industry: 68.75% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.35
Quick Ratio 0.35
JNH.CA Yearly Current Assets VS Current LiabilitesJNH.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

3

3. Growth

3.1 Past

JNH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -29.59%.
JNH shows a strong growth in Revenue. In the last year, the Revenue has grown by 52.74%.
Measured over the past years, JNH shows a very strong growth in Revenue. The Revenue has been growing by 45.61% on average per year.
EPS 1Y (TTM)-29.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.17%
Revenue 1Y (TTM)52.74%
Revenue growth 3Y70.65%
Revenue growth 5Y45.61%
Sales Q2Q%6.27%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
JNH.CA Yearly Revenue VS EstimatesJNH.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for JNH. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JNH.CA Price Earnings VS Forward Price EarningsJNH.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JNH.CA Per share dataJNH.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

JNH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JACK NATHAN MEDICAL CORP

TSX-V:JNH (6/2/2025, 7:00:00 PM)

0.005

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners36.27%
Ins Owner ChangeN/A
Market Cap435.50K
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.02
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.31
BVpS-0.14
TBVpS-0.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -155.33%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-87.41%
ROA(5y)-87.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover4
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 159.45%
Cap/Sales 7.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.35
Quick Ratio 0.35
Altman-Z -9.29
F-Score3
WACC4.14%
ROIC/WACCN/A
Cap/Depr(3y)257.56%
Cap/Depr(5y)269.84%
Cap/Sales(3y)15.97%
Cap/Sales(5y)13.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.17%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)52.74%
Revenue growth 3Y70.65%
Revenue growth 5Y45.61%
Sales Q2Q%6.27%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-79.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-299.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-538.38%
OCF growth 3YN/A
OCF growth 5YN/A